Tyra Biosciences’ (TYRA) Buy Rating Reaffirmed at HC Wainwright

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $23.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 29.50% from the company’s previous close.

Separately, Wedbush restated an “outperform” rating and set a $28.00 price target on shares of Tyra Biosciences in a research report on Thursday, March 21st.

Tyra Biosciences Trading Down 1.5 %

TYRA opened at $17.76 on Friday. The stock has a market capitalization of $932.76 million, a P/E ratio of -11.03 and a beta of 1.08. The stock has a 50-day moving average price of $17.09 and a 200-day moving average price of $15.05. Tyra Biosciences has a 12-month low of $10.38 and a 12-month high of $20.67.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Tuesday, March 19th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.05). On average, equities research analysts predict that Tyra Biosciences will post -1.89 EPS for the current year.

Insider Buying and Selling at Tyra Biosciences

In related news, COO Daniel Bensen sold 1,733 shares of the firm’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $20.09, for a total value of $34,815.97. Following the completion of the sale, the chief operating officer now owns 431,951 shares of the company’s stock, valued at $8,677,895.59. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 6,229 shares of company stock valued at $124,736 in the last 90 days. Insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently bought and sold shares of TYRA. Simplex Trading LLC lifted its position in Tyra Biosciences by 198.1% during the third quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock valued at $27,000 after buying an additional 1,335 shares during the period. Federated Hermes Inc. boosted its stake in Tyra Biosciences by 1,244.2% during the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock worth $29,000 after acquiring an additional 1,916 shares in the last quarter. AJOVista LLC purchased a new stake in Tyra Biosciences in the fourth quarter worth about $59,000. Exchange Traded Concepts LLC increased its stake in shares of Tyra Biosciences by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 9,531 shares of the company’s stock valued at $132,000 after purchasing an additional 2,417 shares in the last quarter. Finally, Corton Capital Inc. purchased a new position in shares of Tyra Biosciences during the third quarter valued at approximately $152,000. 84.14% of the stock is owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.